Viruses Treatment Articles

Transcription Factors Stat5 Promotes Growth Of Human Prostate Cancer Cells In Vivo

July 23, 2017

ORLANDO, FL (UroToday) - Stat5a/b is the key mediator of prolactin (Prl) effects in prostate cancer cells via activation of Jak2. Prl is a locally produced growth factor in human prostate cancer. Prl protein expression and constitutive activation of Stat5a/b are associated with high histological grade of clinical prostate cancer. Moreover, activation of Stat5a/b in primary prostate cancer predicts early disease recurrence. Here, we inhibited Stat5a/b by several different methodological approaches. Our goal was to establish a proof-of-principle that Stat5a/b is critical for prostate cancer cell viability in vitro and for prostate tumor growth in vivo.

These investigators inhibited Stat5a/b in prostate cancer cells by antisense oligonucleotides, RNA interference or by adenoviral expression of a dominant-negative mutant of Stat5a/b (DNStat5a/b). Moreover, Stat5a/b activity was suppressed in human prostate cancer xenograft tumors in nude mice by adenoviral delivery of DNStat5a/b. Stat5a/b regulation of BclXLand Cyclin-D1 protein levels was evaluated by antisense suppression of Stat5a/b protein expression followed by Western blotting.

They found that inhibition of Stat5a/b by antisense oligonuleotides, RNA interference, or adenoviral expression of DNStat5a/b all effectively kills prostate cancer cells. They also demonstrate that Stat5a/b is critical for human prostate cancer xenografts growth in nude mice. Stat5a/b effects on the viability of prostate cancer cells involve Stat5a/b-regulation of BclXL and Cyclin-D1 protein levels.

This work establishes Stat5a/b as a therapeutic target protein for prostate cancer.

Presented by Ayush Dagvadorj, MD, Robert A Kirken, MD, James Karras, MD, Marja T Nevalainen, MD, at the Annual Meeting of the American Urological Association (AUA) - May 17 - 22, 2008. Orange County Convention Center - Orlando, Florida, USA.

Reported by UroToday Contributing Editor Christopher P. Evans, MD, FACS

UroToday - the only urology website with original content global urology key opinion leaders actively engaged in clinical practice.

To access the latest urology news releases from UroToday, go to: www.urotoday

Copyright © 2008 - UroToday